Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore
The specialty chemicals firm is pivoting into finished dosage manufacturing with a deal valuing the target at 15.5% of its own market cap.
— 2 earlier stories on Anupam Rasayan India Ltd. →What's new
- Anupam Rasayan will pay ₹299 per share to acquire a 43.30% stake in Bliss GVS Pharma.
- A mandatory open offer for an additional 26% stake is set at the same ₹299 price.
- The deal marks a formal entry into finished dosage manufacturing for the company.
Why this matters
This acquisition changes the business profile for Anupam Rasayan. Moving from specialty chemicals into finished pharmaceutical products requires a different operational model. At ₹2,198.54 crore, the deal is material, representing 15.5% of the company's ₹14,172 crore market capitalization.
What we're watching
- The success rate of the mandatory open offer for the 26% stake.
- Integration costs as the company moves into finished dosage manufacturing.
- How the market values the combined entity's new business mix.
The full read
Anupam Rasayan is spending ₹2,198.54 crore to take control of Bliss GVS Pharma. The deal structure involves an initial purchase of a 43.30% stake for ₹1,369.51 crore at ₹299 per share, followed by a mandatory open offer for another 26% at the same price. The company also has the option to acquire an additional 4.90%. This move marks a departure from Anupam Rasayan’s core specialty chemicals business, signaling a entry into finished dosage manufacturing. With Bliss GVS reporting a turnover of ₹1,001 crore last year, the acquisition is a expansion. At 15.5% of Anupam Rasayan’s ₹14,172 crore market capitalization, the deal is well above the materiality threshold for mid-cap firms. The integration of these two distinct manufacturing models is the primary test for management in the coming quarters.
Questions answered
- What is the total cost of the acquisition?
- The total consideration is approximately ₹2,198.54 crore. This covers the initial 43.30% stake purchase for ₹1,369.51 crore and the 26% open offer for ₹829.03 crore.
- What is the price per share for the acquisition?
- Anupam Rasayan is paying ₹299 per share for both the initial stake purchase and the mandatory open offer.
- What does Bliss GVS Pharma do?
- Bliss GVS manufactures niche pharmaceutical products, specifically focusing on suppositories and tablets. It reported a turnover of ₹1,001 crore in the last financial year.
- How much of the company is Anupam Rasayan acquiring?
- Anupam Rasayan is acquiring up to 74.20% of the equity and control of Bliss GVS. This includes an initial 43.30% stake, a 26% open offer, and optional shares for an additional 4.90%.
Story so far
All notes on ANURAS →- Today · 7:39 PM IST Anupam Rasayan buys control of Bliss GVS Pharma for ₹2,200 crore
- today Anupam Rasayan revenue jumps 65% in FY26 as margins slip
- today Anupam Rasayan buys 74% of Bliss GVS Pharma to enter drug sector